Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis

Semin Thromb Hemost. 1998;24(6):605-12. doi: 10.1055/s-2007-996061.

Abstract

Laboratory studies were performed on six female patients (ranging in age from 1 to 31 years) with ligneous conjunctivitis, which we regard as a systemic condition consisting of ligneous conjunctivitis and other pseudomembranous lesions. Plasminogen levels were severely reduced in all six patients; five patients were homozygous, and one patient was double heterozygous for type I plasminogen deficiency. Of family members tested, 11 of 12 parents and two of six siblings tested were diagnosed as heterozygous. No thrombotic episodes had occurred in any of the patients. Polymorphonuclear (PMN) elastase protein levels were markedly elevated in all, significantly more so in the homozygous patients (range 88 to 335 ng/mL; normal range, 20+/-10 ng/mL) than in the heterozygous patient (58 ng/mL). Of 11 parents examined, only 1 mother had normal PMN elastase (27 ng/mL, with plasminogen antigen 60% and plasminogen functional activity 86%), whereas values were moderately elevated (range 42 to 110 ng/mL) in the other 10 parents examined. After plasminogen substitution, PMN elastase levels consistently decreased but did not reach normal values. We interpret our findings as indicating that non-plasmin-induced fibrinolytic processes, possibly mediated via elastase, may be intensified in patients with plasminogen deficiency.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Antifibrinolytic Agents*
  • Child
  • Child, Preschool
  • Conjunctivitis / drug therapy
  • Conjunctivitis / enzymology
  • Conjunctivitis / pathology*
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Fibrinolysin / metabolism
  • Homozygote
  • Humans
  • Infant
  • Leukocyte Elastase / blood
  • Plasminogen / deficiency*
  • Plasminogen / genetics*
  • Plasminogen / therapeutic use
  • alpha-2-Antiplasmin / metabolism

Substances

  • Antifibrinolytic Agents
  • Fibrin Fibrinogen Degradation Products
  • alpha-2-Antiplasmin
  • fibrin fragment D
  • plasmin-plasmin inhibitor complex
  • Plasminogen
  • Leukocyte Elastase
  • Fibrinolysin